UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging

Morote, Juan; Pye, Hayley; Campistol, Miriam; Celma, Anna; Regis, Lucas; Semidey, Maria; de Torres, Ines; ... Emberton, Mark; + view all (2023) Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging. BJU International , 132 (2) pp. 188-195. 10.1111/bju.15998. Green open access

[thumbnail of Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance.pdf]
Preview
Text
Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance.pdf - Accepted Version

Download (1MB) | Preview

Abstract

OBJECTIVES: The use of mpMRI has been a significant advance in the diagnosis of clinically significant prostate cancer (ISUP Grade Group ≥2, csPCa) and is recommended in most current guidelines. Proclarix® is a novel CE-marked biomarker test aiding in the identification of csPCa. The aim of the study was the assessment of the clinical performance of Proclarix alone or in combination with mpMRI to predict csPCa. PATIENTS AND METHODS: The study included blood samples from 721 men undergoing mpMRI followed by biopsy at University College London (UCL), London, and Vall d'Hebron University Hospital, Barcelona. Samples were tested blindly. The Proclarix-MRI model combining prostate volume, Proclarix and mpMRI results was trained using the UCL cohort (n=159) and validated in the Vall d'Hebron cohort (n=562). Its diagnostic performance was established in correlation to biopsy outcome and compared to available clinical parameters and risk calculators. RESULTS: Clinical performance of the Proclarix-MRI model in the validation cohort did not significantly differ from the training cohort and resulted in a sensitivity for csPCa of 90%, 90% NPV and 66% PPV. The Proclarix-MRI score's specificity (68%) was significantly (p<0.001) better compared to MRI-ERSPC risk score (51%), Proclarix (27%) or mpMRI (28%) alone. In addition, Proclarix by itself was found to be useful in the MRI PI-RADS 3 subgroup by outperforming PSA density in terms of specificity (25% vs 13%, p=0.004) at 100% sensitivity. CONCLUSION: When combined with mpMRI and prostate volume, Proclarix reliably predicted csPCa and ruled out men with no or indolent cancer. A large reduction of two thirds of unneeded biopsies was achieved. Proclarix can further be used with high confidence to reliably detect csPCa in men with an indeterminate PI-RADS 3 mpMRI. Despite these encouraging results, further validation is needed.

Type: Article
Title: Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/bju.15998
Publisher version: https://doi.org/10.1111/bju.15998
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: PSA, Proclarix, Proclarix-MRI score, biomarkers, biopsy, mpMRI, prostate cancer, thrombospondin-1, cathepsin D, diagnosis
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci > Department of Targeted Intervention
URI: https://discovery.ucl.ac.uk/id/eprint/10166174
Downloads since deposit
11Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item